Sciele Pharma and Plethora Solutions Announce Positive Phase III … – PR-Inside.com (Pressemitteilung)
Nov.09, 2008 in
News
Sciele Pharma and Plethora Solutions Announce Positive Phase III ... PR-Inside.com (Pressemitteilung), Austria - European Phase III double-blind placebo-controlled study of PSD502 for the treatment of premature ejaculation ('PE') has met its three co-primary endpoints ... |

Leave a Reply